ReNeuron Group Plc (RENE) Stock Rating Reaffirmed by N+1 Singer

ReNeuron Group Plc (LON:RENE)‘s stock had its “corporate” rating reiterated by stock analysts at N+1 Singer in a research report issued to clients and investors on Monday.

ReNeuron Group Plc (LON:RENE) opened at 1.75 on Monday. The company’s 50 day moving average price is GBX 1.74 and its 200 day moving average price is GBX 1.92. ReNeuron Group Plc has a 52-week low of GBX 1.65 and a 52-week high of GBX 3.67. The firm’s market cap is GBX 55.38 million.

COPYRIGHT VIOLATION WARNING: This article was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at

About ReNeuron Group Plc

ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company’s products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP).

Receive News & Ratings for ReNeuron Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group Plc and related companies with's FREE daily email newsletter.

Leave a Reply